H.C. Wainwright Downgrades Aldeyra Therapeutics (ALDX) to Neutral

March 18, 2026 6:33 AM

H.C. Wainwright analyst Matt Caufield downgraded Aldeyra Therapeutics (NASDAQ: ALDX) from Buy to Neutral with a price target of $2.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found